CCL18 in a multiplex urine-based assay for the detection of bladder cancer

Virginia Urquidi, Jeongsoon Kim, Myron Chang, Yunfeng Dai, Charles J. Rosser, Steve Goodison

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

The early detection of bladder cancer (BCa) is pivotal for successful patient treatment and management. Through genomic and proteomic studies, we have identified a number of bladder cancer-associated biomarkers that have potential clinical utility. In a case-control study, we examined voided urines from 127 subjects: 64 tumor-bearing subjects and 63 controls. The urine concentrations of the following proteins were assessed by enzyme-linked immunosorbent assay (ELISA); C-C motif chemokine 18 (CCL18), Plasminogen Activator Inhibitor 1 (PAI-1) and CD44. Data were compared to a commercial ELISA-based BCa detection assay (BTA-Trak

Original languageEnglish (US)
Article numbere37797
JournalPloS one
Volume7
Issue number5
DOIs
StatePublished - May 21 2012

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this